Deamination of aliphatic amines by type B monoamine oxidase and semicarbazide-sensitive amine oxidase; pharmacological implications

  • P. H. Yu
  • B. A. Davis
  • A. A. Boulton
  • D. M. Zuo
Conference paper
Part of the Journal of Neural Transmission book series (NEURAL SUPPL, volume 41)


Straight and branched chain aliphatic monoamines, which are not normal tissue constituents, are deaminated selectively by type B monoamine oxidase (MAO-B). They exhibit a high affinity towards the active site of MAO-B and this made them very useful pharmacologically. An anticon-vulsant prodrug, Milacemide [2-(N-pentyl)glycinamide] is deaminated by MAO-B and this facilitates a mechanism of delivering glycine into the CNS. We have found that 2-propyl-pentylamine (2-propyl-1-aminopentane) and N-(2-propylpentyl)glycinamide are also converted by MAO-B to valproic acid and glycine both in vitro and in vivo; these compounds, however, cause severe tremor. By attaching a propargylamine group the resultant series of aliphatic propargylamine derivatives have been shown to be very potent selective MAO-B inhibitors. They are chemically quite different from most other MAO-B inhibitors, since they do not possess any aromatic structures. The relatively short chain aliphatic propargylamines, i.e. N-2-pentyl-N-methylpropargylamine and N-2-hexyl-N-methylpropargylamine, are 4 to 5 times more potent and more selective than selegiline (1-deprenyl) with respect to the inhibition of MAO-B in brain following oral administration.


Monoamine Oxidase Aliphatic Amine Amine Oxidase Carbon Chain Length SSAO Activity 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Baba S, Watanabe Y, Gejyo F, Arakwa M (1984) High-performance liquid Chromatographic determination of serum aliphatic amines in chronic renal failure. Clin Chim Acta 136: 49–56.PubMedCrossRefGoogle Scholar
  2. Battersby AR, Buckley DG, Staunton J, Williams PJ (1979) Studies of enzyme-mediated reactions, part 10. Stereochemical course of the dehydrogenation of stereospecifically labelled 1-amino-heptanes by the amine oxidase from rat liver mitochondria (E.C. J Chem Soc (Perkin I) 10: 2550–2558.CrossRefGoogle Scholar
  3. Birkmayer W, Knoll J, Riederer P, Hars V, Marton J (1985) Increased life expectancy resulting from addition of L-deprenyl to Madopar treatment in Parkinson’s disease: a long-term study. J Neural Transm 64: 113–127.PubMedCrossRefGoogle Scholar
  4. Birkmayer W, Knoll J, Riederer P, Youdim MBH (1983) (-)-Deprenyl leads to prolongation of 1-Dopa efficacy in Parkinson’s disease. Mod Probi Pharmacopsy-chiatry 19: 170–176.Google Scholar
  5. Blaschko H, Richter D, Schlossman H (1937) The oxidation of adrenaline and other amines. Biochem J 31: 2187–2196.PubMedGoogle Scholar
  6. Blau K (1961) Chromatographic methods for the study of amines from biological material. Biochem J 80: 193–200.PubMedGoogle Scholar
  7. Callingham BA, Barrand MA (1987) Some properties of semicarbazide-sensitive amine oxidase. J Neural Transm 23: 37–54.Google Scholar
  8. Cao Danh H, Strolin-Benedetti M, Doster P, Mousset A (1985) Age-related changes in monoamine oxidase and semicarbazide-sensitive amine oxidase activities of rat aorta. J Pharm Pharmacol 37: 354–357.CrossRefGoogle Scholar
  9. Cohen G (1990) Monoamine oxidase and oxidative stress of dopaminergic synapses. J Neural Transm [Suppl] 32: 229–238.Google Scholar
  10. Davis EJ, De Ropp RS (1961) Metabolic origin of urinary methylamine in the rat. Nature 190: 636–637.PubMedCrossRefGoogle Scholar
  11. De Varebeke PJ, Cavalier R, David-Remacle M, Youdim MBH (1988) Formation of the neurotransmitter glycine from the anticonvulsant milacemide is mediated by brain monoamine oxidase-B. J Neurochem 50: 1011–1016.CrossRefGoogle Scholar
  12. Handelmann GE, Nevins ME, Mueller LL, Arnolde SM, Cordi AA (1989) Milacemide, a glycine prodrug, enhances performance of learning tasks in normal and amnestic rodents. Pharmacol Biochem Behav 34: 823–828.PubMedCrossRefGoogle Scholar
  13. Heikkila RE, Manzino L, Cabbat FS, Duvoisin RC (1984) Protection against the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine by monoamine oxidase Inhibitors. Nature 311: 467–469.PubMedCrossRefGoogle Scholar
  14. Heinonen EH, Myllyla V, Sotaniemi K, Lammintausta R, Salonen JS, Anttila M, Savijarvi M, Rinne UK (1989) Pharmacokinetics and metabolism of selegiline. Acta Neurol Scand 126: 93–99.Google Scholar
  15. Hayes BE, Clarke DE (1990) Semicarbazide-sensitive amine oxidase activity in strep-tozotocin diabetic rats. Res Comm Chem Pathol Pharmacol 69: 71–83.Google Scholar
  16. Kapeller-Adler R, Toda K (1932) über das Vorkommen von Monomethylamine im Harn. Biochem Z 248: 403–425.Google Scholar
  17. Klein R, Klein BEK, Moss SE, Davis MD, DeMets DL (1989) The Wisconsin epidemiologie study of diabetic retinopathy. IX. Four-year incidence and progression of diabetic retinopathy when age at diagnosis is less than 30 years. Arch Ophthalmol 107: 237–243.PubMedCrossRefGoogle Scholar
  18. Knoll J, Dallo J, Yen TT (1989) Striatal dopamine, sexual activity and lifespan longevity of rats treated with (—)deprenyl. Life Sci 45: 525–531.PubMedCrossRefGoogle Scholar
  19. Langston JW (1990) Selegiline as neuroprotective therapy in Parkinson’s disease: concepts and controversies. Neurology 40: 61–66.PubMedGoogle Scholar
  20. Lewinsohn R (1981) Amine oxidase in human blood vessels and non-vascular smooth muscle. J Pharm Pharmacol 33: 569–575.PubMedCrossRefGoogle Scholar
  21. Lowis S, Eastwood MA, Brydon WG (1985) The influence of creatinine, lecithin and choline feeding on aliphatic amine production and excretion in rat. Br J Nutr 54: 43–51.PubMedCrossRefGoogle Scholar
  22. Lyles GA, Bertie KH (1987) Properties of a semicarbazide-sensitive amine oxidase in rat articular cartilage. Pharmacol Toxicol [Suppl] 1: 33.Google Scholar
  23. McEwen CMJr, Castell DO (1967) Abnormalities of serum monoamine oxidase in chronic liver disease. J Lab Clin Med 70: 36–47.PubMedGoogle Scholar
  24. Milgram NW, Racine RJ, Nellis P, Mendonca A, Ivy GO (1990) Maintenance on 1-deprenyl prolongs life in aged male rats. Life Sci 47: 415–420.PubMedCrossRefGoogle Scholar
  25. Nixon R (1972) Volatile amines in mouse brain: a radioassay with picogram sensitivity. Anal Biochem 48: 460–470.PubMedCrossRefGoogle Scholar
  26. Precious E, Gunn CE, Lyles GA (1988) Deamination of methylamine by semicarbazide-sensitive amine oxidase in human umbilical artery and rat aorta. Biochem Pharmacol 37: 707–713.PubMedCrossRefGoogle Scholar
  27. Pugh CEM, Quastel JH (1937) Oxidation of aliphatic amines by brain and other tissues. Biochem J 31: 286–291.PubMedGoogle Scholar
  28. Rau L (1991) Hypertension, endothelium, and cardiovascular risk factors. Am J Med 90 [Suppl] 2A: 13S–18S.Google Scholar
  29. Rechenberger J (1940) Über die flüchtigen Alkylamine im menschlichen Stoffwechsel. II. Mitteilung: Ausscheidung im Harn nach oraler Zufuhr. Hoppe-Seyl Z 256: 275–284.CrossRefGoogle Scholar
  30. Robinson BJ (1985) Stereoselectivity and isozyme selectivity of monoamine oxidase inhibitors: enantiomers of amphetamine, N-methylamphetamine and deprenyl. Biochem Pharmacol 34: 4105–4108.PubMedCrossRefGoogle Scholar
  31. Salo PT, Tatton WG (1991) Deprenyl reduces the death of motoneurons caused by axotomy. J Neurosci Res 31: 394–400.CrossRefGoogle Scholar
  32. Schayer RW, Smiley LR, Kaplan HE (1952) The metabolism of epinephrine containing isotopic carbon. J Biol Chem 198: 545–551.PubMedGoogle Scholar
  33. Smith AD, Jepson JB (1967) Chromatography of urinary and tissue amines and amino alcohols as 2,4-dinitrophenyl derivatives prepared with 2-nitrobenzenesulfonic acid. Anal Biochem 18: 36–45.CrossRefGoogle Scholar
  34. Steiner G (1981) Diabetes and atherosclerosis. Diabetes [Suppl] 30: 1–7.Google Scholar
  35. Strolin-Benedetti M, Sontag N, Boucher T, Kan JP (1981) Aliphatic amines as MAO substrates in the rat: the effect of selective inhibitors on the deamination of n-pentylamine. In: Usdin E, Weiner N, Youdim MBH (eds) Function and regulation of monoamine enzymes: basic and clinical aspects. MacMillan, London, pp 527–538.Google Scholar
  36. Symes HL, Missala K, Sourkes TL (1971) Iron and riboflavine-dependent metabolism of a monoamine in the rat in vivo. Science 174: 153–155.PubMedCrossRefGoogle Scholar
  37. Tatton WG, Greenwood CE (1992) Rescue of dying neurons: a new action for deprenyl in MPTP Parkinsonism. J Neurosci Res 30: 666–672.CrossRefGoogle Scholar
  38. Tenne M, Youdim MBH, Ulitzur S, Finberg JPM (1985) Deamination of aliphatic amines by monoamine oxidase A and B studied using a bioluminescence technique. J Neurochem 44: 1373–1377.PubMedCrossRefGoogle Scholar
  39. The Parkinson Study Group (1989) Effect of deprenyl in the progression of disability in early Parkinson’s disease. N Engl J Med 321: 1364–1371.CrossRefGoogle Scholar
  40. Tetrud JW, Langston JW (1989) The effect of deprenyl (selegiline) on the natural history of Parkinson’s disease. Science 245: 519–522.PubMedCrossRefGoogle Scholar
  41. Trézl L, Török G, Vasvéri G, Pipek J (1992) Formation of burst chemiluminescence, excited aldehydes, and singlet oxygen in model reactions and from carcinogenic compounds in rat liver S9 fractions. In: Tyihak E (ed) Role of formaldehyde in biological systems. Hung Biochem Society, Sopron, pp 111–124.Google Scholar
  42. Tryding N, Nilsson SE, Tufvesson G, Berg R, Carlstrom S, Elmfors B, Nilsson JE (1969) Physiological and pathological influences on serum monoamine oxidase level. Scand J Clin Lab Invest 23: 79–84.PubMedCrossRefGoogle Scholar
  43. van Dorsser W, Barris D, Cordi A, Roba J (1983) Anticonvulsant activity of milace-mide. Arch Int Pharmacodyn 266: 239–249.PubMedGoogle Scholar
  44. von Korff RW, Wolfe AR (1984) Saturated amines and diamines as substrates which inhibit beef liver mitochondrial monoamine oxidase. J Bioenerg Biomem 16: 597–609.CrossRefGoogle Scholar
  45. Wibo M, Duong AT, Godfraind T (1980) Subcellular location of semicarbazide-sensitive amine oxidase in rat aorta. Eur J Biochem 112: 87–94.PubMedCrossRefGoogle Scholar
  46. Yu PH (1990) Oxidative deamination of aliphatic amines by rat aorta semicarbazide-sensitive amine oxidase. J Pharm Pharmacol 42: 882–884.PubMedCrossRefGoogle Scholar
  47. Yu PH (1989) Deamination of aliphatic amines of different chain lengths by rat liver monoamine oxidase A and B. J Pharm Pharmacol 41: 205–208.PubMedCrossRefGoogle Scholar
  48. Yu PH (1986) Monoamine oxidase. In: Boulton AA, Baker GB, Yu PH (eds) Neuromethods V: neurotransmitter enzymes. Humana Press, NJ, pp 235–272.Google Scholar
  49. Yu PH, Davis BA (1991a) 2-Propyl-laminopentane, its deamination by monoamine oxidase and semicarbazide-sensitive amine oxidase, conversion to valproic acid and behavioral effects. Neuropharmacology 30: 507–515.PubMedCrossRefGoogle Scholar
  50. Yu PH, Davis DA (1991b) Simultaneous delivery of valproic acid and glycine to the brain, deamination of 2-propylpentylglycinamide by monoamine oxidase B. Mol Chem Neuropathol 15: 37–49.PubMedCrossRefGoogle Scholar
  51. Yu PH, Davis DA, Boulton AA (1992) Aliphatic propargylamines: potent selective irreversible monoamine oxidase B inhibitors. J Med Chem 35: 3705–3713.PubMedCrossRefGoogle Scholar
  52. Yu PH, Zuo DM (1992a) (E)-4-Fluoro-beta-fluoroethylene benzene butamine (MDL-72974A) as a highly potent inhibitor for semicarbazide-sensitive amine oxidase from vascular tissues and serum of different species. Biochem Pharmacol 43: 307–312.PubMedCrossRefGoogle Scholar
  53. Yu PH, Zuo DM (1992b) Methylamine, a potential endogenous toxin for vascular tissues: formation of formaldehyde via enzymatic deamination and the cytotoxic effects on endothelial cells. Diabetes 42: 594–603.CrossRefGoogle Scholar
  54. Zeisel SH, Wishnok JS, Blusztjan JK (1983) Formation of methylamines from ingested choline and lecithin. J Pharmacol Exp Ther 225: 320–324.PubMedGoogle Scholar

Copyright information

© Springer-Verlag 1994

Authors and Affiliations

  • P. H. Yu
    • 1
  • B. A. Davis
    • 1
  • A. A. Boulton
    • 1
  • D. M. Zuo
    • 1
  1. 1.Neuropsychiatric Research Unit, Department of PsychiatryUniversity of SaskatchewanSaskatoonCanada

Personalised recommendations